The AhR signaling pathway elevates the expression of β-catenin and of Wnt5a/b in the tumor tissue of patients with inflammatory breast cancer (IBC) that overexpresses AhR and its target gene/protein CYP1B1 [118]. This evidence concerns the gene WNT5A and inflammatory breast carcinoma.